Skip to main content
ACG 2024 Annual Meeting Main banner
Icon Legend
This session is not in your Favorites.
This session is in your Favorites. Click again to remove it.
Presentation Icons
ACG Award Winner
ACG Award Winner
ACG Newsworthy Abstract
ACG Newsworthy Abstract
Registration Required
Registration Required
No CME
No CME
On-Demand Video
On-Demand Video
Livestream
Livestream
Back

Oral Paper Presentation

Annual Scientific Meeting
Paper/Abstract Presentations

Plenary Session 4B - IBD

Wednesday, October 30, 2024
8:30 AM – 10:15 AM ET
Location: Terrace Ballroom 2-3

Livestream

Presentations:

  • 8:30 AM – 8:40 AM ET
    Fecal Microbiota Transplantation (FMT) With Bezlotoxumab Was Not Better Than FMT Alone in Inflammatory Bowel Disease Patients and Recurrent Clostridioides difficile Infection Results from a Randomized Controlled Trial

    Presenting Author: Jessica R. Allegretti, MD, MPH, FACG – Harvard Medical School

  • 8:40 AM – 8:50 AM ET
    Major Adverse Cardiovascular Events in Patients With IBD Taking Anti-TNF vs JAK Inhibitors: A Propensity Matched Cohort Analysis

    Presenting Author: Saqr Alsakarneh, MD (he/him/his) – University of Missouri - Kansas City School of Medicine

  • 8:50 AM – 9:00 AM ET
    Impact of Gender-Affirming Hormone Therapy in Transgender and Gender Non-Conforming Patients With Inflammatory Bowel Disease

    Presenting Author: Audrey Bennett, MD (she/her/hers) – Vanderbilt University Medical Center

  • 9:00 AM – 9:10 AM ET
    Respiratory Syncytial Virus Vaccine is Associated With Better Outcomes in Inflammatory Bowel Disease Patients over 60 Years Old: A US Propensity-Matched Study

    Presenting Author: Osama Hamid, MD – University of Texas Southwestern Medical Center

  • 9:10 AM – 9:20 AM ET
    Real World Comparison of Effectiveness, Durability, and Safety of First-Line Advanced Therapies for Ulcerative Proctitis

    Presenting Author: Rahul Dalal, MD, MPH – Brigham and Women's Hospital

  • 9:20 AM – 9:30 AM ET
    Efficacy and Safety of Upadacitinib Maintenance Treatment in Patients With Moderately to Severely Active Crohn’s Disease: Two Year Results From the U-ENDURE Long-Term Extension Study

    Presenting Author: Edward V. Loftus, Jr., MD, FACG – Mayo Clinic College of Medicine and Science

  • 9:30 AM – 9:40 AM ET
    Efficacy of Mirikizumab by Baseline Disease Location in Moderately to Severely Active Crohn’s Disease: Results of the Phase 3 VIVID-1 Study

    Presenting Author: Edward Barnes, MD, MPH, FACG – University of North Carolina at Chapel Hill School of Medicine

  • 9:40 AM – 9:50 AM ET
    Efficacy and Safety of Subcutaneous Guselkumab Induction Therapy in Patients With Moderately to Severely Active Crohn’s Disease: Results Through Week 48 From the Phase 3 GRAVITI Study

    Presenting Author: Remo Panaccione, MD – University of Calgary

  • 9:50 AM – 10:00 AM ET
    Week 48 Efficacy Of Guselkumab And Ustekinumab In Crohn’s Disease Based On Prior Response/Exposure To Biologic Therapy: Results From The GALAXI 2 and 3 Phase 3 Studies

    Presenting Author: David T. Rubin, MD, FACG (he/him/his) – University of Chicago Medicine

  • 10:00 AM – 10:10 AM ET
    TUSCANY-2: A Dose-Ranging Phase IIb Study Evaluating Efficacy and Safety of RO7790121, an Antibody Against Tumor Necrosis Factor-Like Ligand 1A (Anti-TL1A) in Adults With Moderately to Severely Active Ulcerative Colitis

    Presenting Author: Jessica R. Allegretti, MD, MPH, FACG – Harvard Medical School